Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
Phase 3 N=52 Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Heart Failure, Diastolic · Pulmonary Hypertension
Primary: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization — -2.4; -4.7 mmHG
Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…
Phase 2 N=31 Interleukin-1 Blockade in HF With Preserved EF
Heart Failure With Normal Ejection Fraction
Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
Phase 4 N=37 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
Phase 4 N=50 BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart Failure With Preserved Ejection Fraction · Hypertension
Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017
Phase 4 N=324 Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Chronic Heart Failure With Preserved Systolic Function
Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…
N/A N=71 Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome
Heart Failure
Primary: Carotid-femoral Pulse Wave Velocity — -0.3; 0.4 m/s — p=0.28
Phase 3 N=504 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)…
Phase 3 N=6,263 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Heart Failure With Preserved Ejection Fraction
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
Phase 2 N=38 Dapagliflozin (DAPA) Effects in HFpEF
Heart Failure With Preserved Ejection Fraction
Primary: Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise — -6.6; -0.4 mmHg — p=0.027
Phase 3 N=2,572 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Heart Failure With Preserved Ejection Fraction
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001
Phase 2 N=142 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Heart Failure With Preserved Ejection Fraction
Primary: Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 — 108.39; 106.27 percentage of baseline NT-proBNP — p=0.7923
Phase 2 N=44 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Heart Failure · Congestive Heart Failure
Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio
N/A N=40 Chronotropic Incompetence in Patients With HFpEF
Heart Failure
Primary: Cardiac Beta-receptor Sensitivity — 0.254; 0.156; 0.365 beats per ng/kg/min ISO
N/A N=52 Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Normal Ejection Fraction
Primary: E/e' (Early Mitral Inflow Doppler Velocity to the Early Diastolic Mitral Annulus Velocity) — 10.4; 9.9 ratio
Phase 2 N=25 Cilostazol for HFpEF
Heart Failure With Preserved Ejection Fraction
Primary: KCCQ-12 — 47; 39 units on a scale
Phase 3 N=30 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
N/A N=10 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Exercise Capacity at 6 Weeks — 659.9; 300.5 seconds — p=0.47
Phase 2 N=196 A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure With Preserved Ejection Fraction
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Study Drug-related TEAEs — 61; 4; 6; 72 Participants
Phase 2 N=30 A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
Heart Failure With Preserved Ejection Fraction
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 23 Participants
Phase 2 N=15 Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min
Phase 3 N=315 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD) — 5.0; 10.0 Meter (m) — p=0.3660
N/A N=100 Exercise Intolerance in Elderly Patients With Diastolic Heart Failure
Heart Failure, Diastolic · Obesity
Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001